Download MendeleyDesign and Structure-Activity Relationships of Novel Inhibitors of Human Rhinovirus 3C Protease.
Kawatkar, S.P., Gagnon, M., Hoesch, V., Tiong-Yip, C., Johnson, K., Ek, M., Nilsson, E., Lister, T., Olsson, L., Patel, J., Yu, Q.(2016) Bioorg Med Chem Lett 26: 3248
- PubMed: 27265257
- DOI: https://doi.org/10.1016/j.bmcl.2016.05.066
- Primary Citation of Related Structures:
5FX5, 5FX6 - PubMed Abstract:
Human rhinovirus (HRV) is a primary cause of common cold and is linked to exacerbation of underlying respiratory diseases such as asthma and COPD. HRV 3C protease, which is responsible for cleavage of viral polyprotein in to proteins essential for viral life-cycle, represents an important target. We have designed proline- and azetidine-based analogues of Rupintrivir that target the P2 pocket of the binding site. Potency optimization, aided with X-ray crystallography and quantum mechanical calculations, led to compounds with activity against a broad spectrum of HRV serotypes. Altogether, these compounds represent alternative starting points to identify promising leads in our continual efforts to treat HRV infections.
Organizational Affiliation:
AstraZeneca Infection Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, MA, United States. Electronic address: sameer.kawatkar@astrazeneca.com.
